Semaglutide vs Telmisartan
FDA Approved vs FDA Approved
synergistic Mechanism-based · 60% Semaglutide helps counteract the insulin-disrupting effects of Telmisartan. A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
Semaglutide Telmisartan
Weight 4,113.64 Da 514.62 Da
Half-life ~7 days (168 hours) ~24 hours
Chain 31 amino acids —
Type GLP-1 receptor agonist Benzimidazole derivative (C33H30N4O2)
Key Benefits
Semaglutide
01 15-20% average body weight reduction
02 Established cardiovascular protection
03 Convenient once-weekly dosing options
04 Comprehensive safety data from extensive trials
05 Flexible injectable and oral formulations
Telmisartan
01 Potent 24-hour blood pressure reduction with once-daily dosing
02 Protection against AAS-induced left ventricular hypertrophy and cardiac remodeling
03 Nephroprotection through reduced intraglomerular pressure and proteinuria
04 Unique partial PPAR-gamma agonism improving insulin sensitivity and lipid metabolism
05 No negative impact on exercise performance, VO2 max, or recovery
06 Reduction of pathological vascular remodeling and arterial stiffness
07 Longest half-life of all ARBs ensuring consistent 24-hour coverage
08 Well-tolerated with a low incidence of side effects compared to ACE inhibitors (no dry cough)
Dosing Protocols
Semaglutide
0.25mg starting, titrate to 1-2.4mg weekly / Once weekly (same day each week)
Weight Loss Initiation 0.25mg Weekly x 4 weeks, then increase
Weight Loss Maintenance 2.4mg Weekly (after 16-week titration)
Diabetes Management 0.5-1mg Weekly
Cardiovascular Protection 0.5-1mg Weekly
Tolerability-Based 0.25-2.4mg Weekly (individualized)
Telmisartan
20-80 mg/day / Once daily
Side Effects
Semaglutide
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Telmisartan
Dizziness or lightheadedness, particularly during the first few days or after dose increases
Mild hypotension, especially in volume-depleted individuals or those on concurrent antihypertensives
Upper respiratory tract infection symptoms (sinusitis, pharyngitis) - reported in clinical trials at rates similar to placebo
Back pain and myalgia (uncommon but reported)
Fatigue
Contraindications
Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy or breastfeeding
History of pancreatitis
Pregnancy (Category D - can cause fetal injury and death; discontinue immediately if pregnancy is detected)
Bilateral renal artery stenosis
Known hypersensitivity to telmisartan or any excipients
Concurrent use with aliskiren in patients with diabetes or renal impairment (eGFR <60)
Severe hepatic impairment or biliary obstruction (telmisartan is eliminated primarily via biliary excretion)
Research Evidence
Semaglutide Telmisartan
Status FDA Approved FDA Approved
References 9 studies 5 studies
Latest 2025-06 2023
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.